{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vedolizumab+300+mg+IV", "query": { "intervention": "Vedolizumab 300 mg IV" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 25, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vedolizumab+300+mg+IV&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-28T22:10:41.507Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03196427", "title": "Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ulcerative Colitis", "Crohn's Disease" ], "interventions": [ { "name": "Vedolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 59, "start_date": "2018-07-30", "completion_date": "2025-07-17", "has_results": true, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-09-28T22:10:41.507Z", "location_count": 9, "location_summary": "Los Angeles, California • Orange, California • San Francisco, California + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03196427" }, { "nct_id": "NCT02497469", "title": "An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colitis, Ulcerative" ], "interventions": [ { "name": "Vedolizumab", "type": "DRUG" }, { "name": "Adalimumab placebo", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Vedolizumab placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 771, "start_date": "2015-06-29", "completion_date": "2019-01-18", "has_results": true, "last_update_posted_date": "2020-01-28", "last_synced_at": "2026-09-28T22:10:41.507Z", "location_count": 77, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 70 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02497469" }, { "nct_id": "NCT02760615", "title": "Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Colitis, Ulcerative", "Crohn Disease" ], "interventions": [ { "name": "Caffeine", "type": "DRUG" }, { "name": "Losartan", "type": "DRUG" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "Dextromethorphan", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Vedolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 0, "start_date": "2016-11-01", "completion_date": "2020-08-01", "has_results": false, "last_update_posted_date": "2020-10-27", "last_synced_at": "2026-09-28T22:10:41.507Z", "location_count": 2, "location_summary": "Cypress, California • Miami, Florida", "locations": [ { "city": "Cypress", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02760615" }, { "nct_id": "NCT06257706", "title": "VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Moderately to Severely Active Crohn's Disease", "Crohn Disease", "Disease Crohn" ], "interventions": [ { "name": "Vedolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Alimentiv Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 304, "start_date": "2024-08-07", "completion_date": "2029-02-06", "has_results": false, "last_update_posted_date": "2026-01-15", "last_synced_at": "2026-09-28T22:10:41.507Z", "location_count": 3, "location_summary": "Los Angeles, California • Charleston, South Carolina • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Charleston", "state": "South Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06257706" }, { "nct_id": "NCT02790138", "title": "A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pouchitis" ], "interventions": [ { "name": "Vedolizumab Placebo", "type": "DRUG" }, { "name": "Ciprofloxacin", "type": "DRUG" }, { "name": "Vedolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 102, "start_date": "2016-10-12", "completion_date": "2021-02-02", "has_results": true, "last_update_posted_date": "2022-02-24", "last_synced_at": "2026-09-28T22:10:41.507Z", "location_count": 10, "location_summary": "Chicago, Illinois • Evanston, Illinois • Minneapolis, Minnesota + 7 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02790138" }, { "nct_id": "NCT03138655", "title": "Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ulcerative Colitis", "Crohn's Disease" ], "interventions": [ { "name": "Vedolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 89, "start_date": "2017-11-08", "completion_date": "2020-05-26", "has_results": true, "last_update_posted_date": "2020-12-21", "last_synced_at": "2026-09-28T22:10:41.507Z", "location_count": 27, "location_summary": "Los Angeles, California • Orange, California • San Francisco, California + 22 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Wilmington", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT03138655" }, { "nct_id": "NCT03142321", "title": "Defining Predictors of RT Response to Vedolizumab in IBD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Crohn Disease of Small Intestine" ], "interventions": [ { "name": "Vedolizumab 300 MG Injection [Entyvio]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2018-06-08", "completion_date": "2024-10-28", "has_results": true, "last_update_posted_date": "2025-09-17", "last_synced_at": "2026-09-28T22:10:41.507Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03142321" }, { "nct_id": "NCT05442567", "title": "A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis", "Crohn's Disease" ], "interventions": [ { "name": "Vedolizumab IV", "type": "DRUG" }, { "name": "No Intervention", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 240, "start_date": "2023-05-16", "completion_date": "2033-02-07", "has_results": false, "last_update_posted_date": "2026-05-07", "last_synced_at": "2026-09-28T22:10:41.507Z", "location_count": 22, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05442567" }, { "nct_id": "NCT06581328", "title": "A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Ulcerative Colitis", "Crohn's Disease" ], "interventions": [ { "name": "Vedolizumab IV", "type": "DRUG" }, { "name": "Vedolizumab SC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 200, "start_date": "2025-03-27", "completion_date": "2028-06-01", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-09-28T22:10:41.507Z", "location_count": 101, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 89 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06581328" }, { "nct_id": "NCT04779320", "title": "A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn's Disease (CD)" ], "interventions": [ { "name": "Vedolizumab IV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 120, "start_date": "2022-02-10", "completion_date": "2027-09-13", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-09-28T22:10:41.507Z", "location_count": 22, "location_summary": "Phoenix, Arizona • Los Angeles, California • San Diego, California + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Kissimmee", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04779320" } ] }